Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 680

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 680
---
 with respect to any intention by such entity to deregister SPAC Class A Shares or prohibit or terminate the listing of SPAC Class A Shares on the NASDAQ. Other than as contemplated by this Agreement, SPAC has taken no action that is designed to voluntarily terminate the registration of SPAC Class A Shares under the Securities Exchange Act. As of the Effective Date, SPAC has not received any written or, to the Knowledge of SPAC, oral deficiency notice from NASDAQ relating to the continued listing requirements of SPAC Class A Shares that, if required to be disclosed, has not been publicly disclosed.”

(h) Section 8.3 — Listing . Section 8.3 of the BCA is hereby amended and restated in its entirety to read as follows:

“During the Pre-Closing Period, SPAC shall use its commercially reasonable efforts to ensure that the SPAC Class A Shares are continually quoted for public trading on a nationally recognized medium of no less significance than the OTC Pink Market or any national securities exchange acceptable to the Company; provided, that the Parties acknowledge and agree that from and after the Closing, the Parties intend to list on NASDAQ only the ParentCo Common Stock and the ParentCo Public Warrants.”

(i) Section 8.17 — Payments to Sponsor . Section 8.17 of the BCA is hereby amended and restated in its entirety to read as follows:

“ Section 8.17 Payments to Arrow Capital, Mauritius .

If the SPAC Operating Expenses at the Closing are less than $5,000,000, the Company shall, at, or promptly following the Closing, pay $250,000 to Arrow Capital, Mauritius.”

Section 8.18 — Post-Closing Issuance . Section 8.18 of the BCA is hereby deleted in its entirety and replaced with “Reserved.”

(j) Section 8.19 — International New Drug Application . Section 8.19 of the BCA is hereby deleted in its entirety and replaced with “Reserved.”

(k) Section 10.1(g) — Termination . Section 10.1(g) of the BCA is hereby amended and restated in its entirety to read as follows:

“(g) by the Company by written notice to SPAC if SPAC fails, at any time prior to the Effective Time, to maintain the listing of publicly traded Equity Securities of SPAC on a nationally recognized medium of no less significance than the OTC Pink Market or any national securities exchange acceptable to the Company;”

(l) Company